v3.26.3
Segment Information - Summary of Revenue, Expenses and Net Loss for the Segment and is Reconciled to Net Loss on a Consolidated Basis (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Net sales $ 121,469 $ 67,455 $ 292,212 $ 176,731
Total cost of sales 48,028 38,477 134,121 130,073
Expenses        
Research and development 49,337 75,174 170,675 229,067
General and administrative 38,575 34,555 116,796 115,922
Depreciation and amortization 9,497 9,007 27,536 26,422
Restructuring charges   5,143   5,143
Net Loss (22,271) (91,253) (148,631) (319,074)
Single Reportable Segment        
Segment Reporting [Line Items]        
Net sales 121,469 67,455 292,212 176,731
Cost of goods sold (excluding depreciation and amortization) [1] 41,558 34,734 120,196 119,206
Stock-based compensation 1,721 1,408 4,276 5,977
Royalties 4,749 2,335 9,649 4,890
Total cost of sales 48,028 38,477 134,121 130,073
Expenses        
Research and development 44,566 70,163 155,709 207,780
General and administrative 17,681 17,865 54,998 61,286
Sales and marketing 15,552 11,209 46,205 32,141
Depreciation and amortization 9,497 9,007 27,536 26,422
Restructuring charges   5,143   5,143
Other segment items 8,416 6,844 22,274 32,960
Total expenses [2] 95,712 120,231 306,722 365,732
Net Loss $ (22,271) $ (91,253) $ (148,631) $ (319,074)
[1] Cost of goods sold represents inventory and period costs related to overhead, manufacturing costs of Amtagvi®, and reserves associated with excess and obsolete inventory, as well as costs associated with the purchases and sales of Proleukin®. Also included are manufacturing and period costs incurred for Amtagvi® that do not meet specifications or a patient is unable to receive the infusion. For patients that can be administered Amtagvi® as part of a clinical trial in an expanded or early access program, or single-patient investigational new drug submission, costs are recorded as research and development expenses based on the fact the Company receives clinical data related to these infusions. This category is provided to the CODM on a quarterly basis in comparison to that of previous quarters for review as these costs are controllable costs that indicate operating performance of the Company.
[2] Other segment items include costs that are not considered significant expense segments nor reviewed by the CODM on a regular basis. Such amount includes stock-based compensation expenses (excluding stock-based compensation included in cost of sales), interest income, other income and expenses, and income tax benefits.